Bavarian Nordic on acquisition trail for more production capacity  

Success on the US market has spurred Bavarian Nordic to look around Europe for ready made vaccine production facilities

Danish biotech company Bavarian Nordic's success on the US market has spurred the company to look around Europe with an eye to acquiring existing vaccine production facilities. Internet newspaper Infopaq reports that according to the daily broadsheet Berlingske Tidende, Bavarian Nordic is in discussions with two European companies regarding acquisition of vaccine production facilities. Bavarian needs additional production facilities in order to meet US requirements for large scale production. The company stands to save several months if it can acquire ready made production capacity rather than take the new build route. Bavarian Nordic has declined to name the parties to the discussions or put any numbers on potential acquisition deals, but it does confirm multimillion sums would be involved.


Bavarian Nordic recently gained the second part of a US government award to further develop a third generation smallpox vaccine (MVA-BN). The company's H1 2003 turnover more than quadrupled from DKK 121 million (USD 17.8 million) to DKK 500 million (USD 73.5 million) with sales of Bavarian Nordic’s smallpox vaccine to the US government strongly influencing the result.


Link > Bavarian Nordic

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×